Lotus Pharmaceuticals (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced today that Lotus and Teraju Pharma, a leading pharmaceutical company based in Malaysia, have entered into a strategic partnership for the Malaysian market. Teraju has an extensive commercial reach in Malaysia and sources a broad range of branded or generic equivalent medicines from all over the world to fulfill the needs of the local market. This partnership allows Teraju to market and promote Lotus’ branded products across various therapeutic areas utilizing Teraju’s extensive infrastructure and broad relationships.

The collaboration is in-line with Lotus’ strategic plan to expand in Southeast Asia and the partnership plans to launch a portfolio of products beginning in the fourth quarter of 2023 in the therapeutic categories of oncology, cardio-metabolic and ophthalmology. These fast-tracked launches are expected to give an immediate boost to Lotus’ presence in Malaysia. According to IQVIA data, the overall market size of the selected products is USD 12 Million and has experienced strong growth over the last 5 years.

Petar Vazharov, Lotus’ Chief Executive Officer, said: “We are delighted at our new collaboration with Teraju.  This partnership will enable us to establish a substantial presence in Malaysia, particularly in the oncology sector, which leverages high-quality manufacturing and rich pipeline of products.”